| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:MS-073;MS073
CAS:129716-45-6
Purity:98% Package:5 mg
|
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:MS-073
CAS:129716-45-6
Purity:98%
|
|
| Product Name: | MS 073 | | Synonyms: | MS 073;1-(Quinolin-5-yloxy)-3-[4-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten)-5-yl]piperazin-1-yl]-2-propanol;CP-162398;1-Piperazineethanol, 4-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)-α-[(5-quinolinyloxy)methyl]- | | CAS: | 129716-45-6 | | MF: | C31H33N3O2 | | MW: | 479.61 | | EINECS: | | | Product Categories: | | | Mol File: | 129716-45-6.mol |  |
| | MS 073 Chemical Properties |
| | MS 073 Usage And Synthesis |
| Description | MS-073, also known as CP-162398, is a P-glycoprotein inhibitor (P-gp). MS-073 was compared with verapamil with regard to its ability to overcome MDR in vitro and in vivo. MS-073 at 0.1 microM almost completely reversed in vitro resistance to vincristine (VCR) in VCR-resistant P388 cells. MS-073 also reversed in vitro VCR, adriamycin (ADM), etoposide, and actinomycin D resistance in ADM-resistant human myelogenous leukemia K562 (K562/ADM) cells, MS-073 reverses MDR by competitively inhibiting drug binding to P-glycoprotein. |
| | MS 073 Preparation Products And Raw materials |
|